Moderna
MRNA
$1.66 (1.38%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
GlobeNewsWire • 11 hours ago • MRNA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAZacks Investment Research • 12 hours ago • MRNA
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?PRNewsWire • 2 days ago • MRNA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNAZacks Investment Research • 3 days ago • MRNA
Why Moderna (MRNA) Dipped More Than Broader Market TodayAccesswire • 3 days ago • MRNA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNACharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.